Hacker Timesnew | past | comments | ask | show | jobs | submitlogin

Thyroid cancer sounds more scary than it actually is. It's one of the weakest forms of cancer, and it's extremely easy to treat if caught early enough. Also, living without a thyroid is no big deal.

Somebody very near and dear to me was diagnosed with thyroid cancer ten years ago, and now has no thyroid. She's hardly inconvenienced by it & hasn't even gained any weight since then. Just gotta remember to take those T4 tablets in the morning, is all.

Point is: If you weigh in the balance [lives saved or QALY gained due to GLP agonist administration] vs. [lives lost or QALY lost due to thyroid cancer secondary to GLP agonist administration], it's not even going to be remotely close. "Lives saved" will probably win by an enormous margin, maybe a factor of twenty or so.



Is it wise to minimize thyroid cancer or ablation just because you know someone who fared well afterwards?


People hear the word "cancer" and think "death sentence." (Or, at the very least, an extremely difficult ordeal.) It's a scary word. Yet thyroid cancer is generally a mild disease -- especially mild as cancer goes -- and almost invariably nonfatal if caught early enough.

If GLP-1 inhibitors get people screened for thyroid cancers more frequently, or lead to improved treatments for thyroid cancer, they will almost certainly lead to a reduction in thyroid cancer deaths -- even if, as some surmise, they are responsible for an increase in thyroid cancer cases. Even without this effect, if you balance [QALY lost] versus [QALY gained] GLP-1 agonists should come out so far ahead that it's almost laughable.

In any case, I believe it is wise to talk about these things openly and without fear.


> inhibitor

> agonist

nit: these are not the same

Also, not all thyroid cancers are created equally (like papillary vs medullary), not every one taking GLP-1 RAs are morbidly obese, etc.


Excuse the mix-up.

> Also, not all thyroid cancers are created equally (like papillary vs medullary)

Granted, but how is this relevant? I've heard that those drugs may -- this is still, as yet, uncertain -- increase the likelihood of follicular thyroid cancer, which is a very weak type. I have not heard that they increase one's likelihood of coming down with the anaplastic variant. (The only truly deadly one, but quite rare.) If caught early enough, papillary, follicular, and medullary are all easily treatable and indeed curable.

> not every one taking GLP-1 RAs are morbidly obese

Again, sure, but how is it relevant?




Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact

Search: